TABLE 1.
Comparison of in vitro anti-RSV activity of PC786 with those of known antiviral agentsa
| Compound (n = 3) | RSV A2 |
RSV B WST |
Cell viability,CC50 (nM) | ||
|---|---|---|---|---|---|
| IC50 (nM) | IC90 (nM) | IC50 (nM) | IC90 (nM) | ||
| PC786 | 0.50 ± 0.0014 | 0.63 ± 0.035 | 27.3 ± 0.77 | 57.1 ± 3.87 | >14,000 |
| AZ-27 | 26.4 ± 1.16 | 60.0 ± 6.75 | >1,580 | >1,580 | >15,800 |
| BI compound D | 57.6 ± 1.53 | >333 | 47.8 ± 2.96 | >1,660 | 600c |
| Ribavirin | >16,400 | >16,400 | 10,300 | >16,400 | 202,000 ± 80,000 |
| ALS-8112b | 455 ± 16.0 | 1,130 ± 77.9 | 647 ± 44.2 | 2,130 ± 363 | >341,000 |
| GS-5806 | 0.45 ± 0.018 | 0.93 ± 0.098 | 0.17 ± 0.043 | >126 | >18,800 |
| TMC35315 | 0.78 ± 0.0093 | 1.29 ± 0.015 | 0.85 ± 0.017 | 2.63 ± 0.19 | 7,944 ± 2,326 |
a
CC50, concentration required for 50% cytotoxicity; IC50 and IC90, concentrations required for 50 and 90% inhibition, respectively; WST, Washington.
b
ALS-8112 was added 24 h prior to virus inoculation (although all others were treated simultaneously with virus infection).
c
n = 2 (343 and 857 nM).